NASDAQ:CRNX Crinetics Pharmaceuticals (CRNX) Stock Price, News & Analysis $84.95 0.00 (0.00%) As of 09/1/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Crinetics Pharmaceuticals Stock (NASDAQ:CRNX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CRNX alerts:Sign Up Key Stats Today's Range$84.95▼$84.9550-Day Range$83.52▼$84.9552-Week Range$30.25▼$85.01VolumeN/AAverage Volume2.43 million shsMarket Capitalization$9.01 billionP/E RatioN/ADividend YieldN/APrice Target$81.00Consensus RatingHold Company Overview Crinetics Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing orally delivered, nonpeptide therapies for endocrine diseases and other conditions with significant unmet medical needs. The company’s research platform is designed to create selective small-molecule medicines that can act on clinically important hormone receptors. Crinetics’ lead product candidate is paltusotine, an oral somatostatin receptor type 2 agonist being developed for endocrine disorders including acromegaly and carcinoid syndrome. Unlike injectable therapies commonly used in these conditions, paltusotine is intended to provide an oral treatment option. The company is also advancing additional discovery and development programs targeting other endocrine and rare diseases. Founded in 2008, Crinetics is headquartered in San Diego, California, and serves patients and healthcare markets internationally through its research and clinical development activities. The company was co-founded by Scott Struthers, Ph.D., who has served as its president and chief executive officer.AI Generated. May Contain Errors. Read More Crinetics Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks20th Percentile Overall ScoreCRNX MarketRank™: Crinetics Pharmaceuticals scored higher than 20% of companies evaluated by MarketBeat, and ranked 816th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.1 / 5Analyst RatingHold Consensus RatingCrinetics Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.24, and is based on no strong buy ratings, 5 buy ratings, 11 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Crinetics Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageCrinetics Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Crinetics Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Crinetics Pharmaceuticals are expected to grow in the coming year, from ($4.83) to ($4.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Crinetics Pharmaceuticals is -16.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Crinetics Pharmaceuticals is -16.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCrinetics Pharmaceuticals has a P/B Ratio of 7.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Crinetics Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.71% of the float of Crinetics Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCrinetics Pharmaceuticals has a short interest ratio ("days to cover") of 2.39, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Crinetics Pharmaceuticals has recently increased by 3.92%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCrinetics Pharmaceuticals does not currently pay a dividend.Dividend GrowthCrinetics Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Crinetics Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for CRNX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Crinetics Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $120,000.00 in company stock.Percentage Held by Insiders3.80% of the stock of Crinetics Pharmaceuticals is held by insiders.Percentage Held by Institutions98.51% of the stock of Crinetics Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Crinetics Pharmaceuticals' insider trading history. Receive CRNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRNX Stock News HeadlinesCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Recommendation of "Hold" by BrokeragesSeptember 20 at 4:28 AM | americanbankingnews.comCrinetics Pharmaceuticals, Inc.(NasdaqGS:CRNX) dropped from S&P TMI IndexSeptember 3, 2026 | marketscreener.comMThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this supercycle - and says that may be conservative. Billionaire Pierre Lassonde has argued for $19,000. Former CIA advisor Jim Rickards targets $27,000 based on a federal revaluation of the gold supply. But the bigger opportunity may not be gold itself. A 'backdoor' gold-linked asset has historically multiplied gold's move by 10x or more - returning 846%, 1,668%, 1,847%, and 1,915% in the last supercycle.September 20 at 1:00 AM | Traders Agency (Ad)Crinetics Pharmaceuticals, Inc.(NasdaqGS:CRNX) dropped from S&P Global BMI IndexSeptember 3, 2026 | marketscreener.comMCrinetics Pharmaceuticals, Inc.(NasdaqGS:CRNX) dropped from S&P Pharmaceuticals Select Industry IndexSeptember 3, 2026 | marketscreener.comMVertex Pharmaceuticals Closes Crinetics Pharmaceuticals AcquisitionSeptember 1, 2026 | finance.yahoo.com$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger—CRNX, PSBQ, D, and NEEAugust 7, 2026 | globenewswire.comCrinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 3, 2026 | globenewswire.comSee More Headlines CRNX Stock Analysis - Frequently Asked Questions How have CRNX shares performed this year? Crinetics Pharmaceuticals' stock was trading at $46.55 at the beginning of the year. Since then, CRNX shares have increased by 82.5% and is now trading at $84.95. How were Crinetics Pharmaceuticals' earnings last quarter? Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) posted its earnings results on Monday, August, 3rd. The company reported ($1.14) earnings per share for the quarter, topping the consensus estimate of ($1.18) by $0.04. The firm's quarterly revenue was up 2336.9% compared to the same quarter last year. When did Crinetics Pharmaceuticals IPO? Crinetics Pharmaceuticals (CRNX) raised $96 million in an IPO on Wednesday, July 18th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO. Who are Crinetics Pharmaceuticals' major shareholders? Crinetics Pharmaceuticals' top institutional investors include BlackRock Inc. (9.20%), Wellington Management Group LLP (6.72%), Jupiter Topco LLC (4.30%) and First Light Asset Management LLC (1.28%). Insiders that own company stock include Richard Scott Struthers, Stephen F Betz, Marc Wilson, Jeff E Knight, Tobin Schilke, Dana Pizzuti, Alan Seth Krasner, James Hassard, Matthew K Fust, Coelho Rogerio Vivaldi, Stephanie Okey and Isabel Kalofonos. View institutional ownership trends. How do I buy shares of Crinetics Pharmaceuticals? Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Crinetics Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Crinetics Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), ServiceNow (NOW) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/03/2026Today9/20/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CRNX's financial health is in the Green zone, according to TradeSmith. CRNX has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CRNX CIK1658247 Webwww.crinetics.com Phone(858) 450-6464FaxN/AEmployees210Year Founded2008Price Target and Rating Average Price Target for Crinetics Pharmaceuticals$81.00 High Price Target$95.00 Low Price Target$52.00 Potential Upside/Downside-4.6%Consensus RatingHold Rating Score (0-4)2.24 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($5.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$465.32 million Net Margins-1,189.88% Pretax Margin-1,189.45% Return on Equity-44.22% Return on Assets-39.77% Debt Debt-to-Equity RatioN/A Current Ratio15.57 Quick Ratio15.53 Sales & Book Value Annual Sales$7.70 million Price / Sales1,170.54 Cash FlowN/A Price / Cash FlowN/A Book Value$11.23 per share Price / Book7.56Miscellaneous Outstanding Shares106,100,000Free Float102,063,000Market Cap$9.01 billion OptionableOptionable Beta0.08 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:CRNX) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...Banyan Hill Publishing | SponsoredNew Form of AI Could Ignite the ‘Great Wealth Rotation’Marc Chaikin, a 60-year Wall Street veteran who worked alongside Paul Tudor Jones and Steve Cohen, says a new ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
